What is AstraZeneca(AZD7442)?

Phase1 study on AZD7442a monoclonal-antibody combination for the prevention and treatment of COVID-19 was initiated by Astra Zeneca plc AZN.AZD7442 was derived from convalescent patients with SARS-CoV-2infection. This comprises a combination of two monoclonal antibodies, AZD8895and AZD1061. Forty-eight healthy Participants aged 18 to 55 years took part in the phase1 study, which they will also ensure the safety, tolerance, and pharmacokinetics of AZD7442. Later this year, data is expected about this study. A bigger late-stage phase II and phase III studies will commence if the data is a positive one after the examination of more than 1,500 antibodies for their capacity to bind and counteract the SARS-CoV-2virus spear protein AZD7442 was identified by AstraZeneca. In partnership with Oxford University, AstraZeneca is developing a COVID-19vaccine.

There aren’t a lot of details that are available about AZD7442 but if you would delve deeper into it, you will realize that this is a type of a possible combination therapy that can be used for some people. The status of this study right now is still in the recruiting stage which means that they are still looking for the right people to participate in the study. With all of the recent happenings, there is a possibility that this will not take place anytime soon. There are different antibodies that are being considered so that this study will still push through. Hopefully, this would be enough to create the right vaccine to completely eradicate COVID 19.